HC
AXSM icon

Henshaw Capital’s Axsome Therapeutics AXSM Stock Holding History

Henshaw Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,036
Closed -$612K – 172
2025
Q3 		$612K Sell
5,036
-1,835
-27% -$207K 0.02% 153
2025
Q2 		$717K Buy
6,871
+731
+12% +$77.4K 0.03% 189
2025
Q1 		$716K Buy
6,140
+659
+12% +$75.1K 0.03% 179
2024
Q4 		$464K Hold
5,481
– – 0.02% 233
2024
Q3 		$493K Buy
5,481
+453
+9% +$39.5K 0.02% 220
2024
Q2 		$405K Buy
5,028
+2,337
+87% +$173K 0.02% 202
2024
Q1 		$215K Buy
+2,691
New +$226K 0.01% 277

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Henshaw Capital's AXSM Position: Q4 2025 in Review

Henshaw Capital sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 5,036 shares — an estimated $612K sold.

Henshaw Capital first reported a position in AXSM in Q1 2024 and held it in 7 quarters. The position peaked at $717K in Q2 2025. 399 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • Henshaw Capital reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Henshaw Capital sold 5,036 Axsome Therapeutics shares in Q4 2025, an estimated $612K.
  • Henshaw Capital first reported a position in Axsome Therapeutics in Q1 2024 and held it in 7 quarters.
  • Henshaw Capital's Axsome Therapeutics position peaked at $717K in Q2 2025.
  • 399 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Henshaw Capital's 13F filing for Q4 2025, filed 28 May 2026.